verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh12770verezdo-12770Research ArticleРЕДАКЦИОННЫЕ СТАТЬИEDITORIALSМетоды коррекции синдрома гипогонадизма у мужчин и отдаленные результаты медикаментозного леченияMethods of correction of hypogonadism syndrome in men and long-term results of drug treatmenthttps://orcid.org/0000-0002-4195-7234РоживановаЕ. Р.RozhivanovaE. R.

Роживанова Екатерина Романовна

117036, Москва, ул. Дм. Ульянова, д. 11

Ekaterina R. Rozhivanova - MD.

11 Dm. Ulyanova street, 117036 Moscow

erozhivanova@mail.ruhttps://orcid.org/0000-0002-5386-4289РоживановР. В.RozhivanovR. V.

Роживанов Роман Викторович - д.м.н.

Roman V. Rozhivanov - MD, PhD.

Roman V. Rozhivanov - MD, PhD.

Moscow

rrozhivanov@mail.ruhttps://orcid.org/0009-0009-1348-161XМорозоваЕ. В.MorozovaE. V.

Морозова Елена Валерьевна

Москва

Elena V. Morozova - MD.

Moscow

https://orcid.org/0009-0006-6107-4494ГайдайчукК. Е.GaidaichukK. E.

Гайдайчук Константин Евгеньевич

Москва

Konstantin E. Gaidaichuk - MD.

Moscow

Gaidaikon@yandex.ruhttps://orcid.org/0000-0002-5634-7877МельниченкоГ. А.Mel’nichenkoG. A.

Мельниченко Галина Афанасьевна - д.м.н., профессор, академик РАН.

Москва

Galina A. Mel’nichenko - MD, PhD, Professor.

Moscow

teofrast2000@mail.ruhttps://orcid.org/0000-0001-8425-0020АндрееваЕ. Н.AndreevaE. N.

Андреева Елена Николаевна - д.м.н., профессор.

Москва

Elena N. Andreeva - MD, PhD, Professor.

Moscow

endogin@mail.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна - д.м.н., профессор, член-корр. РАН.

Москва

Natalya G. Mokrysheva - MD, PhD, Professor.

Moscow

nm70@mail.ruГНЦ ФГБУ Национальный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian FederationГНЦ ФГБУ Национальный медицинский исследовательский центр эндокринологии; Российский университет медициныРоссияEndocrinology Research Centre; Russian University of MedicineRussian Federation202505112025431219Copyright © Роживанова Е.Р., Роживанов Р.В., Морозова Е.В., Гайдайчук К.Е., Мельниченко Г.А., Андреева Е.Н., Мокрышева Н.Г., 20252025Роживанова Е.Р., Роживанов Р.В., Морозова Е.В., Гайдайчук К.Е., Мельниченко Г.А., Андреева Е.Н., Мокрышева Н.Г.Rozhivanova E.R., Rozhivanov R.V., Morozova E.V., Gaidaichuk K.E., Mel’nichenko G.A., Andreeva E.N., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/12770

Синдром гипогонадизма, характеризующийся дефицитом тестостерона, негативно влияет на физическое, метаболическое и психоэмоциональное здоровье мужчин. Основные методы лечения гипогонадизма включают андрогенную заместительную и андрогенную стимулирующую терапию. Андрогенная заместительная терапия, представленная трансдермальными и инъекционными формами тестостерона, эффективно восстанавливает уровень тестостерона, улучшает сексуальную функцию, мышечную массу, минеральную плотность костей и метаболические показатели.

Однако она подавляет сперматогенез, что ограничивает ее применение у мужчин, планирующих отцовство. Андрогенная стимулирующая терапия, включающая гонадотропины, антиэстрогены и ингибиторы ароматазы, стимулирует выработку эндогенного тестостерона и сперматогенез. Гонадотропины демонстрируют высокую эффективность, но их долгосрочное применение осложнено необходимостью частых инъекций и отсутствием отдаленных результатов использования. Проведенные многолетние исследования, представленные в обзоре, подтверждают безопасность и эффективность андрогенной заместительной терапии, но данные по андрогенной стимулирующей терапии ограничены по времени наблюдения максимум двумя годами.

Hypogonadism syndrome, characterized by testosterone deficiency, negatively affects the physical, metabolic and psychoemotional health of men. The main treatments for hypogonadism include androgen replacement and androgen stimulating therapy. Androgen replacement therapy, represented by transdermal and injectable forms of testosterone, effectively restores testosterone levels, improves sexual function, muscle mass, bone mineral density and metabolic parameters.

However, it suppresses spermatogenesis, which limits its use in men planning fatherhood. Androgen stimulating therapy, including gonadotropins, antiestrogens and aromatase inhibitors, stimulates the production of endogenous testosterone and spermatogenesis. Gonadotropins demonstrate high efficacy, but their long-term use is complicated by the need for frequent injections and the lack of long-term results. The long-term studies presented in the review confirm the safety and effectiveness of androgen replacement therapy, but data on androgen stimulating therapy are limited in follow-up time to a maximum of two years.

гипогонадизммужчинытестостеронгонадотропинhypogonadismmentestosteronegonadotropinРабота выполнена по инициативе авторов без привлечения финансированияReferencesTajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab (Seoul). 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab (Seoul). 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760Salonia A, Bettocchi C, Carvalho J, et al. EAU Guidelines on Sexual and Reproductive Health 2021 Update: Male Sexual Dysfunction. Eur Urol . 2021. Аvailable on the EAU website: http://www.uroweb.org/guidelines/Salonia A, Bettocchi C, Carvalho J, et al. EAU Guidelines on Sexual and Reproductive Health 2021 Update: Male Sexual Dysfunction. Eur Urol . 2021. Аvailable on the EAU website: http://www.uroweb.org/guidelines/Wang C, Nieschlag E, Swerdloff R, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol. 2009;55(1):121-130. doi: https://doi.org/10.1016/j.eururo.2008.08.033Wang C, Nieschlag E, Swerdloff R, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol. 2009;55(1):121-130. doi: https://doi.org/10.1016/j.eururo.2008.08.033Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598-1605. doi: https://doi.org/10.1111/andr.12867Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598-1605. doi: https://doi.org/10.1111/andr.12867Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: https://doi.org/10.1210/jc.2018-00229Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: https://doi.org/10.1210/jc.2018-00229Pencina K.M., Travison T.G., Cunningham G.R. et al. (2024). Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. The Journal of Clinical Endocrinology & Metabolism, 109(2), 569–580. doi: https://doi.org/10.1210/clinem/dgad484Pencina K.M., Travison T.G., Cunningham G.R. et al. (2024). Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. The Journal of Clinical Endocrinology & Metabolism, 109(2), 569–580. doi: https://doi.org/10.1210/clinem/dgad484Lee TW, Kao PY, Chen YC, Wang S Te. Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis. Gerontology. 2023. doi: https://doi.org/10.1159/000532062Lee TW, Kao PY, Chen YC, Wang S Te. Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis. Gerontology. 2023. doi: https://doi.org/10.1159/000532062Saad F, Haider KS, Haider A. Effects of long-term testosterone therapy on anthropometric parameters in men with functional hypogonadism and obesity: 12-year observational data from a controlled registry study in a urological setting. Endocr Abstr. May 2021. doi: https://doi.org/10.1530/endoabs.73.AEP162Saad F, Haider KS, Haider A. Effects of long-term testosterone therapy on anthropometric parameters in men with functional hypogonadism and obesity: 12-year observational data from a controlled registry study in a urological setting. Endocr Abstr. May 2021. doi: https://doi.org/10.1530/endoabs.73.AEP162Borges MD J. The Inverse Association between Testosterone Replacement Therapy and Cardiovascular Disease Risk: A Systematic 25-year Review and Meta-Analysis Analysis of Prospective Cohort Studies from 1999 to 2024. International Journal of Cardiovascular Medicine. 2024;3(4):01–8. doi: https://doi.org/10.31579/2834-796X/073Borges MD J. The Inverse Association between Testosterone Replacement Therapy and Cardiovascular Disease Risk: A Systematic 25-year Review and Meta-Analysis Analysis of Prospective Cohort Studies from 1999 to 2024. International Journal of Cardiovascular Medicine. 2024;3(4):01–8. doi: https://doi.org/10.31579/2834-796X/073Brannigan RE. Testosterone Therapy and Male Fertility. / Controversies in Testosterone Deficiency. 2021; р. 57–70. doi: https://doi.org/10.1007/978-3-030-77111-9_6Brannigan RE. Testosterone Therapy and Male Fertility. / Controversies in Testosterone Deficiency. 2021; р. 57–70. doi: https://doi.org/10.1007/978-3-030-77111-9_6Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines—gynecomastia evaluation and management. Andrology. 2019. doi: https://doi.org/10.1111/andr.12636Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines—gynecomastia evaluation and management. Andrology. 2019. doi: https://doi.org/10.1111/andr.12636Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008. doi: https://doi.org/10.1159/000119417Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008. doi: https://doi.org/10.1159/000119417Frizza F, Maggi M, Lotti F. Skin Androgen-Related Disorders: Hormonal Treatment. / European Handbook of Dermatological Treatments. 2023; p.1661–1678. doi: https://doi.org/10.1007/978-3-031-15130-9_147Frizza F, Maggi M, Lotti F. Skin Androgen-Related Disorders: Hormonal Treatment. / European Handbook of Dermatological Treatments. 2023; p.1661–1678. doi: https://doi.org/10.1007/978-3-031-15130-9_147Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. Association between testosterone therapy and change in hematocrit: a systematic review and network metaanalysis of randomized control trials. Fertil Steril. 2021. doi: https://doi.org/10.1016/j.fertnstert.2021.07.960Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. Association between testosterone therapy and change in hematocrit: a systematic review and network metaanalysis of randomized control trials. Fertil Steril. 2021. doi: https://doi.org/10.1016/j.fertnstert.2021.07.960Lenfant L, Leon P, Cancel-Tassin G, et al. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol Semin Orig Investig. 2020;38(8):661-670. doi: https://doi.org/10.1016/j.urolonc.2020.04.008Lenfant L, Leon P, Cancel-Tassin G, et al. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol Semin Orig Investig. 2020;38(8):661-670. doi: https://doi.org/10.1016/j.urolonc.2020.04.008Bhasin S, Travison TG, Pencina KM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism. JAMA Netw Open. 2023;6(12):e2348692. doi: https://doi.org/10.1001/jamanetworkopen.2023.48692Bhasin S, Travison TG, Pencina KM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism. JAMA Netw Open. 2023;6(12):e2348692. doi: https://doi.org/10.1001/jamanetworkopen.2023.48692Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023. doi: https://doi.org/10.1056/nejmoa2215025Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023. doi: https://doi.org/10.1056/nejmoa2215025Čeponis J, Yuen F, Swerdloff RS, Wang C. Testosterone Therapy: Transdermal Androgens. / Testosterone. 2023; p.303–314. doi: https://doi.org/10.1007/978-3-031-31501-5_14Čeponis J, Yuen F, Swerdloff RS, Wang C. Testosterone Therapy: Transdermal Androgens. / Testosterone. 2023; p.303–314. doi: https://doi.org/10.1007/978-3-031-31501-5_14Инструкция по медицинскому применению лекарственного препарата «Андрогель®». Регистрационный номер: ЛС-000869. Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Androgel®». Registratsionnyi nomer: LS-000869. Gosudarstvennyi reestr lekarstvennykh sredstvHill, Alyssa MD; Rabaza, Cristina MD. (2024). Is topical testosterone less likely to cause polycythemia than IM testosterone in patients on testosterone replacement therapy?. Evidence-Based Practice, 27(6), 17–18, June 2024. doi: https://doi.org/10.1097/EBP.0000000000002101Hill, Alyssa MD; Rabaza, Cristina MD. (2024). Is topical testosterone less likely to cause polycythemia than IM testosterone in patients on testosterone replacement therapy?. Evidence-Based Practice, 27(6), 17–18, June 2024. doi: https://doi.org/10.1097/EBP.0000000000002101Yassin A. Testosterone Therapy: Injectable Androgens. / Testosterone. 2023; р.315–330. doi: https://doi.org/10.1007/978-3-031-31501-5_15Yassin A. Testosterone Therapy: Injectable Androgens. / Testosterone. 2023; р.315–330. doi: https://doi.org/10.1007/978-3-031-31501-5_15Инструкция по медицинскому применению лекарственного препарата «Сустанон®-250». Регистрационный номер: П N013419/01. Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Sustanon®-250». Registratsionnyi nomer: P N013419/01. Gosudarstvennyi reestr lekarstvennykh sredstvИнструкция по медицинскому применению лекарственного препарата «Омнадрен® 250». Регистрационный номер: П N014397/01. Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Omnadren® 250». Registratsionnyi nomer: P N014397/01. Gosudarstvennyi reestr lekarstvennykh sredstvИнструкция по медицинскому применению лекарственного препарата «Небидо®». Регистрационный номер: ЛП-№(004023)-(РГ-RU). Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Nebido®». Registratsionnyi nomer: LP-№(004023)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstvИнструкция по медицинскому применению лекарственного препарата «Тестостерона пропионат». Регистрационный номер: ЛП-№(004825)-(РГ-RU). Государственный реестр лекарственных средств[Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Testosterona propionat». Registratsionnyi nomer: LP-№(004825)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstvIde V, Vanderschueren D, Antonio L. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy. Int J Mol Sci. 2020;22(1):21. doi: https://doi.org/10.3390/ijms22010021Ide V, Vanderschueren D, Antonio L. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy. Int J Mol Sci. 2020;22(1):21. doi: https://doi.org/10.3390/ijms22010021Boeri L, Capogrosso P, Salonia A. Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism. Curr Pharm Des. 2021;27(24):2775-2783. doi: https://doi.org/10.2174/1381612826666200523175806Boeri L, Capogrosso P, Salonia A. Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism. Curr Pharm Des. 2021;27(24):2775-2783. doi: https://doi.org/10.2174/1381612826666200523175806Инструкция по медицинскому применению лекарственного препарата «Хорагон®». Регистрационный номер: П N012469/01. Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Khoragon®». Registratsionnyi nomer: P N012469/01. Gosudarstvennyi reestr lekarstvennykh sredstvИнструкция по медицинскому применению лекарственного препарата «Гонадотропин хорионический». Регистрационный номер: ЛП-№(007553)-(РГ-RU). Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Gonadotropin khoriionicheskii». Registratsionnyi nomer: LP-№(007553)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstvJeon G-H, Park C. Successful pregnancy after hCG/hMG treatment in an azoospermic male with idiopathic hypogonadotropic hypogonadism. Indones J Obstet Gynecol. October 2022:238-242. doi: https://doi.org/10.32771/inajog.v10i4.1604Jeon G-H, Park C. Successful pregnancy after hCG/hMG treatment in an azoospermic male with idiopathic hypogonadotropic hypogonadism. Indones J Obstet Gynecol. October 2022:238-242. doi: https://doi.org/10.32771/inajog.v10i4.1604Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. The treatment of hypogonadism in men of reproductive age. Fertil Steril. 2013;99(3):718-724. doi: https://doi.org/10.1016/j.fertnstert.2012.10.052Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. The treatment of hypogonadism in men of reproductive age. Fertil Steril. 2013;99(3):718-724. doi: https://doi.org/10.1016/j.fertnstert.2012.10.052Huijben M, Huijsmans RLN, Lock MTWT, de Kemp VF, de Kort LMO, van Breda JHMK. Clomiphene citrate for male infertility: A systematic review and meta‐analysis. Andrology. 2023;11(6):987-996. doi: https://doi.org/10.1111/andr.13388Huijben M, Huijsmans RLN, Lock MTWT, de Kemp VF, de Kort LMO, van Breda JHMK. Clomiphene citrate for male infertility: A systematic review and meta‐analysis. Andrology. 2023;11(6):987-996. doi: https://doi.org/10.1111/andr.13388Инструкция по медицинскому применению лекарственного препарата «Клостилбегит®». Регистрационный номер: ЛП-№(000161)-(РГ-RU). Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Klostilbegit®». Registratsionnyi nomer: LP-№(000161)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstvWu YC, Sung WW. Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. Pharmaceuticals (Basel). 2024;17(9):1233. doi: https://doi.org/10.3390/ph17091233Wu YC, Sung WW. Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. Pharmaceuticals (Basel). 2024;17(9):1233. doi: https://doi.org/10.3390/ph17091233Awouters M., Vanderschueren D. & Antonio L. (2020). Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism? Andrology, 8(6), 1590–1597. Portico. https://doi.org/10.1111/andr.12725Awouters M., Vanderschueren D. & Antonio L. (2020). Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism? Andrology, 8(6), 1590–1597. Portico. https://doi.org/10.1111/andr.12725Huang WJ. The Roles of Aromatase Inhibitors in Treating Hypogonadism and Male Infertility. Urol Sci. 2022;33(3):114-118. doi: https://doi.org/10.4103/UROS.UROS_28_22Huang WJ. The Roles of Aromatase Inhibitors in Treating Hypogonadism and Male Infertility. Urol Sci. 2022;33(3):114-118. doi: https://doi.org/10.4103/UROS.UROS_28_22Инструкция по медицинскому применению лекарственного препарата «Анастрозол-Промомед». Регистрационный номер: ЛП-№(005165)-(РГ-RU). Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Anastrozol-Promomed». Registratsionnyi nomer: LP-№(005165)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstvИнструкция по медицинскому применению лекарственного препарата «Летрозол». Регистрационный номер: ЛП-№(006372)-(РГ-RU). Государственный реестр лекарственных средствInstruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Letrozol». Registratsionnyi nomer: LP-№(006372)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstvКравцова Н. С., Роживанов Р. В., Курбатов Д. Г. Стимуляция сперматогенеза гонадотропинами и антиэстрогеном при патоспермии и бесплодии мужчин // Проблемы Эндокринологии. 2016;62(2):37-41 doi: https://doi.org/10.14341/probl201662237-41Kravtsova NS, Rozhivanov RV, Kurbatov DG. Stimulation of a spermatogenesis at men gonadotrophins and an antiestrogen at a pathospermia and infertility. Problems of Endocrinology. 2016;62(2):37-41. (In Russ.) doi: https://doi.org/10.14341/probl201662237-41Saylam B, Efesoy O, Çayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011;95(2):809-811. doi: https://doi.org/10.1016/j.fertnstert.2010.09.021Saylam B, Efesoy O, Çayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011;95(2):809-811. doi: https://doi.org/10.1016/j.fertnstert.2010.09.021Wang C, Cunningham G, Dobs A, et al. Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men. J Clin Endocrinol Metab. 2004. doi: https://doi.org/10.1210/jc.2003-032006Wang C, Cunningham G, Dobs A, et al. Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men. J Clin Endocrinol Metab. 2004. doi: https://doi.org/10.1210/jc.2003-032006Fillo J, Breza J, Ondrusova M, et al. Results of long term testosterone replacement therapy in men with abdominal obesity, erectile dysfunction and testosterone deficiency. Bratislava Med J. 2018;119(09):577-580. doi: https://doi.org/10.4149/BLL_2018_061Fillo J, Breza J, Ondrusova M, et al. Results of long term testosterone replacement therapy in men with abdominal obesity, erectile dysfunction and testosterone deficiency. Bratislava Med J. 2018;119(09):577-580. doi: https://doi.org/10.4149/BLL_2018_061Brooke J., Walter D., Muraleedharan V. & Jones T. H. (2012). Testosterone replacement therapy has beneficial effects on Cardiovascular risk factors and liver function in hypogonadal men. Society for Endocrinology BES 2012, United Kingdom. Endocrine Abstracts 28 P163Brooke J., Walter D., Muraleedharan V. & Jones T. H. (2012). Testosterone replacement therapy has beneficial effects on Cardiovascular risk factors and liver function in hypogonadal men. Society for Endocrinology BES 2012, United Kingdom. Endocrine Abstracts 28 P163Alwani M, Al-Zoubi RM, Al-Qudimat A, et al. The impact of longterm Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study. Ann Med Surg. 2021. doi: https://doi.org/10.1016/j.amsu.2021.102748Alwani M, Al-Zoubi RM, Al-Qudimat A, et al. The impact of longterm Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study. Ann Med Surg. 2021. doi: https://doi.org/10.1016/j.amsu.2021.102748Liu PY, Wishart SM, Handelsman DJ. A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency. J Clin Endocrinol Metab. 2002;87(7):3125-3135. doi: https://doi.org/10.1210/jcem.87.7.8630Liu PY, Wishart SM, Handelsman DJ. A Double-Blind, PlaceboControlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency. J Clin Endocrinol Metab. 2002;87(7):3125-3135. doi: https://doi.org/10.1210/jcem.87.7.8630Liu P, Wishart S, Celermajer D, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol. January 2003:55-66. doi: https://doi.org/10.1530/eje.0.1480055Liu P, Wishart S, Celermajer D, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol. January 2003:55-66. doi: https://doi.org/10.1530/eje.0.1480055Yang L., Zhang S. X., Dong Q. et al. (2012). Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience. International Urology and Nephrology, 44(2), 393–399. https://doi.org/10.1007/s11255-011-0065-0Yang L., Zhang S. X., Dong Q. et al. (2012). Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience. International Urology and Nephrology, 44(2), 393–399. https://doi.org/10.1007/s11255-011-0065-0Bayram F, Elbuken G, Korkmaz C, Aydogdu A, Karaca Z, Caklr I. The Effects of Gonadotropin Replacement Therapy on Metabolic Parameters and Body Composition in Men with Idiopathic Hypogonadotropic Hypogonadism. Horm Metab Res. 2015. doi: https://doi.org/10.1055/s-0035-1564252Bayram F, Elbuken G, Korkmaz C, Aydogdu A, Karaca Z, Caklr I. The Effects of Gonadotropin Replacement Therapy on Metabolic Parameters and Body Composition in Men with Idiopathic Hypogonadotropic Hypogonadism. Horm Metab Res. 2015. doi: https://doi.org/10.1055/s-0035-1564252Habous M, Giona S, Tealab A, et al. Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study. BJU Int. 2018. doi: https://doi.org/10.1111/bju.14401Habous M, Giona S, Tealab A, et al. Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study. BJU Int. 2018. doi: https://doi.org/10.1111/bju.14401Debruyne F. M. J., Behre H. M., Roehrborn C. G. et al. (2017). Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU International, 119(2), 216–224. Portico. doi: https://doi.org/10.1111/bju.13578Debruyne F. M. J., Behre H. M., Roehrborn C. G. et al. (2017). Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU International, 119(2), 216–224. Portico. doi: https://doi.org/10.1111/bju.13578Роживанов Р.В., Роживанова Е.Р., Андреева Е.Н., Мельниченко Г.А., Мокрышева Н.Г. Синдром гипогонадизма у мужчин (учебное пособие). – М. ГНЦ, ФГБУ «НМИЦ эндокринологии» Минздрава России, 2025, с. 50Roman V. Rozhivanov, Ekaterina R. Rozhivanova, Elena N. Andreeva, Galina A. Mel’nichenko, Natalya G. Mokrysheva. Sindrom gipogonadizma u muzhchin (uchebnoe posobie). – Moscow: FSBI «NMRC of Endocrinology» of the Ministry of Health of the Russian Federation, 2025:50.Zucker I, Rainer Q, Pai RK, Ramasamy R, Masterson TA. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. 2022. doi: https://doi.org/10.7759/cureus.25543Zucker I, Rainer Q, Pai RK, Ramasamy R, Masterson TA. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. 2022. doi: https://doi.org/10.7759/cureus.25543Rainer Q, Pai R, Zucker I, Ramasamy R, Masterson TA. The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use. Cureus. June 2022. doi: https://doi.org/10.7759/cureus.25826Rainer Q, Pai R, Zucker I, Ramasamy R, Masterson TA. The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use. Cureus. June 2022. doi: https://doi.org/10.7759/cureus.25826

The authors declare that there are no conflicts of interest present.